{"ticker": {"uuid": "3c59053a-e29e-4bc5-9e1e-64cb490bd2e4", "symbol": "VRDN", "name": "Viridian Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Lumvoa\u2019s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNR29uSk1XdV9XREhNejhocjNzUWtfUVpaZmszcXB3NkVLZl9HaFpYVk1oeVYzTTI1TkZFdm1PYkRtREJYdXdmbXRRUGZjZ0tGS1ViQVVyVk1ORnVrN2pEOWd4WS0wODgzUGdld0lrR3h1N0s2OGp6akdjSEtjUk5pZnJ5MlFNaUVfR3B6eDJlMFhxTHN0TE1FVU8ycFdrZw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:48+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMVJZaGRacTlPN0lhMUVONVVxRXZadFhJOTc5NUdKNy1vb0JpLThmWVBBOTNvNWdGOXA1Vmo4SVRIQkgzc1dWMGg5LWkwa2RxSGRGTU1SMnFzdTI5LVI3NE9xNnhwdF8tcE4yYnZ5ZkF5cGRrWVd6QlBidW03SUNSd1JEcGRCeUxpa3pFU3BlNkRlV2NkWVFyZGUxZWtLRVlILUMtQWM5MA?oc=5", "source_name": "Market source", "published_at": "2026-07-15T12:24:01+00:00", "published_display": "15 Jul 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today", "summary": "Viridian Therapeutics (VRDN) stock has dropped 37.8% year-to-date, but despite this decline, valuation checks suggest it remains expensive, trading at a high P/S ratio of 29.7x compared to industry averages. The tailored Fair Ratio further indicates overvaluation, although this c", "url": "https://finance.yahoo.com/markets/stocks/articles/viridian-therapeutics-vrdn-stock-still-051014266.html", "source_name": "Market source", "published_at": "2026-07-15T12:11:55", "published_display": "15 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN6389238 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides key details about the Viridian Therapeutics, Inc. VRDN6389238 bond. It highlights the current coupon rate of 1.75% and indicates that the next interest payment is scheduled for November 16, 2026. The piece also notes that further in-depth coupon data and an ", "url": "https://www.tradingview.com/symbols/FINRA-VRDN6389238/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T04:11:55", "published_display": "15 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN6389238 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Viridian Therapeutics, Inc. bond, VRDN6389238, which has a 1.75% coupon and matures on May 15, 2032. It details the issuer's profile as a biopharmaceutical company focused on autoimmune and rare diseases. The bond has an outstanding amoun", "url": "https://www.tradingview.com/symbols/FINRA-VRDN6389238/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T16:11:55", "published_display": "14 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43", "summary": "Wedbush analyst Laura Chico has reiterated a Buy rating for Viridian Therapeutics (VRDN.US) and maintained a target price of $43. According to TipRanks data, Chico demonstrates a 53.7% success rate and a 14.6% average return over the past year, indicating a positive track record ", "url": "https://www.moomoo.com/news/post/72868295/wedbush-maintains-viridian-therapeutics-vrdnus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-14T14:11:41", "published_display": "14 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval", "summary": "Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its first commercial product, which has positively impacted its stock performance with significant short-term gains. Despite a high Price-to-Sales ratio of 31.5x, suggesting overvaluation compared to industry", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte", "source_name": "Simply Wall Street", "published_at": "2026-07-10T23:41:13", "published_display": "10 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total debt per share of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "This article provides financial data for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its total debt per share. It presents the period, value, and change percentages related to this metric, indicating what appears to be part of a financial report or overview.", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-07-10T12:10:22", "published_display": "10 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total assets of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "The article focuses on the total assets of Viridian Therapeutics, Inc., identifiable by its Hamburg Stock Exchange ticker 1S1. It appears to be a stub or financial data page rather than a detailed news article, providing context within TradingView's platform. The content primaril", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-balance-sheet/total-assets/", "source_name": "TradingView", "published_at": "2026-07-10T11:40:22", "published_display": "10 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tangible book value per share of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "The article provides financial information for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its tangible book value per share. It appears to be a financial data snippet from TradingView, indicating the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-statistics-and-ratios/book-tangible-per-share/", "source_name": "TradingView", "published_at": "2026-07-09T19:05:03", "published_display": "09 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline", "summary": "Viridian Therapeutics, a Nasdaq-listed biotech, is focused on developing antibody-based treatments for thyroid eye disease and similar autoimmune conditions affecting the eye. The company aims to expand its pipeline and collaborate with manufacturing partners to achieve long-term", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/viridian-therapeutics-outlines-eye-disease-strategy-as-nasdaq-listed/69725079", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:39:13", "published_display": "08 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances", "summary": "Viridian Therapeutics (VRDN) is a clinical-stage biotechnology company focusing on autoimmune and rare diseases, particularly advancing its pipeline strategy for thyroid eye disease. The company's lead monoclonal antibody program targets specific immune pathways for this conditio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/viridian-therapeutics-updates-pipeline-plans-as-thyroid-eye-disease/69717392", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:57:00", "published_display": "07 Jul 2026 21:57", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wedbush-sees-commercial-edge-viridian-172141387.html", "source_name": "Insider Monkey", "published_at": "2026-07-06T17:21:41+00:00", "published_display": "06 Jul 2026 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease", "summary": "Viridian Therapeutics recently received FDA approval for Lumvoa (veligrotug-vvze) for both active and chronic thyroid eye disease, marking its first commercial product and a significant shift in its investment narrative. The company now faces the challenge of converting this appr", "url": "https://www.sahmcapital.com/news/content/the-bull-case-for-viridian-therapeutics-vrdn-could-change-following-fda-approval-of-lumvoa-for-thyroid-eye-disease-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T10:10:42", "published_display": "06 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN - Viridian Therapeutics Inc Earnings", "summary": "This article provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also presents earnings per share (EPS) forecasts, insider and institutional ownership ", "url": "https://finviz.com/stock?t=VRDN&b=2&p=d&ty=ea", "source_name": "Finviz", "published_at": "2026-07-05T00:09:40", "published_display": "05 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Viridian Therapeutics Inc (VRDN)", "summary": "This article analyzes hypothetical investments in Viridian Therapeutics Inc (VRDN), detailing the returns of $1,000 invested over 1, 5, and 10 years, and comparing its performance to the S&P 500. It also provides an in-depth company profile, outlining Viridian's focus on developi", "url": "https://www.stocktitan.net/tools/stock-return-calculator/VRDN", "source_name": "Stock Titan", "published_at": "2026-07-04T08:40:34", "published_display": "04 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ajer granted 32,341 Viridian Therapeutics (VRDN) stock options at $18.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQjRrM0xKXzFVWlNleUlEN1dseF9WdzJkYjN2THhNdTdpOG5LcHE4dGYzYXVRejFOcXoyT1l3MGVKTjNfTXhXVndNZEhYaC1rUi0wcUJDaFFUSWJzT0JrcjlPX0tWNU8zd0FaRFJOUjF2ZmJZLU0ySkUxbEpCaHFpWHBHTzdRY2FnM3g0bHVVU3FybUdHanNZbTduSnY4dFFwWkFOZzhfUGdEcjQ2Z09RNDU1ZnA5R28xZklPdnFoYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:17:15+00:00", "published_display": "02 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWWNCY2toUTl2WlJ2X0I3OXo1YVozd2w0YkMxM1FpcWduLXFFTDhOMUQ4bUJDeHlOQm1RelFNZVM1dEN4TllESHUtNEV6ZTI0S2RQUG5GRXBENjk1NG42aWZ2cnJUcGdnQjdidk9uZWJvODFtRkdVMlFnZ3lZRFhrVnRGQXQ2WjFlYUNNSmx0MlhLdEVXLVZweHN4SDdOd2JRV1U3Yi1HQkJua0VIcWxEWUlnUEdSUnk0RkMyb1Jrbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know", "summary": "Shares of Viridian Therapeutics (VRDN) rose 6.3% last week following FDA approval for veligrotug (brand name Lumvoa) for thyroid eye disease (TED), marking the company's entry into the commercial biotechnology sector. Lumvoa is the first FDA-approved TED therapy with labeling for", "url": "https://finance.yahoo.com/healthcare/articles/vrdn-stock-rises-6-3-144100711.html", "source_name": "Market source", "published_at": "2026-07-01T14:41:00", "published_display": "01 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more", "summary": "This edition of Rx Rundown covers significant news in the medical marketing and pharmaceutical industry. Key highlights include Zymeworks acquiring Theravance Biopharma, several FDA approvals and rejections for new and existing drugs, and substantial funding rounds for various bi", "url": "https://www.mmm-online.com/news/rx-rundown-zymeworks-viridian-therapeutics-biocryst-and-more/", "source_name": "Medical Marketing and Media", "published_at": "2026-07-01T11:39:33", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN - Viridian Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short", "url": "https://finviz.com/stock?t=VRDN&ty=oc&ov=chain_strike&s=20", "source_name": "Finviz", "published_at": "2026-07-01T08:10:07", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Wins FDA Approval For Lumvoa, Is The Upside Already Priced In?", "summary": "Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its treatment for thyroid eye disease, leading to a 6% after-hours stock increase. Despite a 40.11% year-to-date drop, the stock shows a 26.99% one-year return, prompting questions about its current valuation", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-wins-fda-approval-for-lumvoa-is-t", "source_name": "Simply Wall Street", "published_at": "2026-07-01T07:10:42", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Viridian's veligrotug for TED as Lumvoa", "summary": "Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking it as the second FDA-approved treatment for the condition. Lumvoa is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in", "url": "https://glance.eyesoneyecare.com/stories/2026-06-30/fda-clears-viridian-s-veligrotug-for-ted-as-lumvoa/", "source_name": "Eyes On Eyecare", "published_at": "2026-06-30T18:53:13", "published_display": "30 Jun 2026 18:53", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/viridian-therapeutics-apos-lumvoa-could-155322062.html", "source_name": "MT Newswires", "published_at": "2026-06-30T15:53:22+00:00", "published_display": "30 Jun 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian may have edge over Amgen in eye drug showdown, analysts argue", "summary": "", "url": "https://finance.yahoo.com/m/c09c12d4-6ec1-3a49-b338-7aa08274d43d/viridian-may-have-edge-over.html", "source_name": "BioPharma Dive", "published_at": "2026-06-30T11:33:00+00:00", "published_display": "30 Jun 2026 11:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-lifts-price-target-viridian-113014022.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:30:14+00:00", "published_display": "30 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED)", "summary": "Viridian Therapeutics announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), following priority review and support from the THRIVE and THRIVE-2 clinical trials. The company plans an immediate launch and has established Viridia", "url": "https://www.visionmonday.com/eyecare/article/viridian-therapeutics-receives-fda-approval-for-lumvoa-for-the-treatment-of-thyroid-eye-disease-ted/", "source_name": "VisionMonday.com", "published_at": "2026-06-30T04:10:13", "published_display": "30 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Viridian Therapeutics Price Target to $43 From $32, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-lifts-viridian-therapeutics-price-185123743.html", "source_name": "MT Newswires", "published_at": "2026-06-29T18:51:23+00:00", "published_display": "29 Jun 2026 18:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Metals Inc (VRDN) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxQN0xkUGVUWFVQeThLRm1peUgwaVhKcjdEb0xJbmE3bXVyMmZaOWlkQTc4cTZYcjAweEx5Y3RKWTJZNDBxWHI2UjNzX3JVLUowcjM3eGpfbWdLMnFiOTgyX0VpMHJPM0FYQUFhNnNJUUVLZVpTaVhicW9WNkdQbVlSVHMzeEdxMmtCRWpiWDVMOGVrS3dTR0xaNDJGRXVuMThfdnBDTkEtQ2plelVKVXN5MnVBN1hvUkpnTlZqUldlZVljakFjeXMyUUpSczRhY0IwcU1WVGlBSzNKLWpJSk9jVFhNNUVrUjhmbHY4RjRDbldXT2pxUjluODY0YzM2X25YNlR0UW1oWmlGelc3QjZtQS1fM2tzOUtwNHFtUmRJVzgwY2xO?oc=5", "source_name": "Moomoo", "published_at": "2026-06-29T17:57:00+00:00", "published_display": "29 Jun 2026 17:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutic stock rating reiterated at Outperform by William Blair", "summary": "William Blair has reiterated its Outperform rating on Viridian Therapeutic (NASDAQ:VRDN) following the company's recent discussion of its newly FDA-approved treatment for thyroid eye disease, Lumvoa. The firm expressed increased confidence in Viridian's commercial readiness and t", "url": "https://www.investing.com/news/analyst-ratings/viridian-therapeutic-stock-rating-reiterated-at-outperform-by-william-blair-93CH-4765927", "source_name": "Investing.com", "published_at": "2026-06-29T17:41:26", "published_display": "29 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)", "summary": "Analysts are showing bullish sentiment towards several healthcare stocks, including Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595), and Sino Biopharmaceutical (SBMFF). Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeu", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3028401/analysts-are-bullish-on-these-healthcare-stocks-viridian-therapeutics-vrdn-genfleet-therapeutics-shanghai-inc-class-h-hk2595/", "source_name": "The Globe and Mail", "published_at": "2026-06-29T08:41:26", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Viridian Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQR09YVWJxZ0E3b0hMTEh5OGxqSkdWbkVkY3NDa1NlbWJDbGdhMTVjc3hFb2drZVlvU3lfSm9ld256V1M2Wk02VG5DTkMxanF4enI5YWhuMGx1UmpDSHVfX2dWeVNESGRQOEkycXQ3YXBjMUd6OEJqV0JheHlJYWVvYVRBX1ZmXzlSdWU4Y1JKampHQkhCejdvLWdfUnNvUWVycHlMU3RyYm1PaFpoWGdB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa\u2122 (veligrotug-vvze) for the Treatment of Thyroid Eye Disease", "summary": "Viridian Therapeutics has received U.S. FDA approval for Lumvoa\u2122 (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking the company's first commercial product. Lumvoa is the first approved treatment for TED with data for both active and chronic forms of the dis", "url": "https://www.biospace.com/press-releases/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-lumvoa-veligrotug-vvze-for-the-treatment-of-thyroid-eye-disease", "source_name": "BioSpace", "published_at": "2026-06-29T07:10:42", "published_display": "29 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All\u2011Stage Thyroid Eye Drug", "summary": "Viridian Therapeutics' stock rose by 7.6% after its drug Lumvoa received FDA approval to treat thyroid eye disease across all stages, making it the first such therapy. This approval shifts Viridian from a development-stage company to a commercial one, with potential for further m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/why-viridian-therapeutics-vrdn-is-up-76-after-fda-clears-fir", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:39:43", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Viridian Therapeutics, Inc. \u2013 NASDAQ:VRDN", "summary": "This article provides financial information for Viridian Therapeutics, Inc. (NASDAQ:VRDN), specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed at the time of publication and offers an overview of the company's financial data on T", "url": "https://www.tradingview.com/symbols/NASDAQ-VRDN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:39:43", "published_display": "28 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Viridian Therapeutics, Inc. \u2013 GETTEX:1S1", "summary": "The article displays the \"Price to earnings forward\" for Viridian Therapeutics, Inc. (1S1) traded on Gettex, indicating that the market was closed with no trades recorded for this metric. It also mentions that the data is provided by ICE Data Services and FactSet, and refers to S", "url": "https://www.tradingview.com/symbols/GETTEX-1S1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:37", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian\u2019s Lumvoa becomes the first FDA-approved TED treatment", "summary": "Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) to treat Thyroid Eye Disease (TED), making it the first approved TED treatment with data for both active and chronic forms of the condition. The approval is supported by positive results from the THRIVE ", "url": "https://www.stocktitan.net/news/VRDN/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-w6eswct1do92.html", "source_name": "Stock Titan", "published_at": "2026-06-27T06:39:43", "published_display": "27 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval", "summary": "Viridian Therapeutics Inc (VRDN) saw its stock jump 6% after-hours following FDA approval of its drug, Lumvoa, for thyroid eye disease (TED). Lumvoa is the first treatment for TED approved for both active and chronic stages of the condition. The approval is based on strong result", "url": "https://stocktwits.com/news-articles/markets/equity/vrdn-stock-jumps-after-hours-as-viridian-wins-first-fda-approval/cZ1225pR7WO", "source_name": "Stocktwits", "published_at": "2026-06-26T23:11:17", "published_display": "26 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm entities report combined stake in Viridian Therapeutics (NASDAQ: VRDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPZmVnMmhxazZaTjBneEtiLWZqbWdqdlNOM1ZtM2ZNREJZM00taUJIOUVJdDBad1V5NENZMi11Z1JLVVd6NzRIa19jeVJYOV9rQmJMbERrNEdiTHNkWkxQaDZYdGgwRW5NTkp1aVdqbkQxWUxVX3JlS0N2b29Uc29xdzNWdGt4YmhLZUhaMGxPZUxWaExWbzlMeng1WUNCV0k5V0Vvay1vVEZydzNYUHljajhtbDRJZnRJUFh0QXducVY3b1BjNjhJd1NfNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves Lumvoa for thyroid eye disease as Viridian (VRDN) readies launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb2t0cmhPd0dKMjFfSTFNWGNzTFJaLTZDWHdITzRYcUpRSmtlTldSa2pzaGIxYmFfZ0tEMDQwem9LeWd4YndMOFVYdzhuNTlxbjlPNlE3WURiTXBkMGlIVTZBXzg3ZklVQm9EMVU1QWJ1SXlsUDliU2h5ZFpkRVpHWFQxem5ScHRRRFJNV0lzZnFva0pvdzgwRFZpSXFmd0lPLU1UbjB6NGJIamRQdnRmT09TY3FSNkhv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOd2pzX0Zyd3FnY0FQR2EwbldnX09FLVhaRG80bk5wN2lQX1VZRG5aSnF6MzMxR3Vkd3JEV3JyOGZ1eS1maG0zdUNHLXVJNGczUzd2eXkxaXJyaEJnNERYLVZkdGxvS2JHYkdzMldqX1VVdkdVdzFjOGxydW81SmtTVmZTU19UZUtfZDZxekRHQzVfeHFfbks2aF9FRlBWUW5pVzZOTWFZOWV0dw?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOVHBoYmJaWFVkX1VCWFZiWEN5R2QtM2liZEVsM3Q4cVRHenRRSG9WRkNZbFFLNU5EMnBOQmVZbEV6Rkh5RkFEdnhuQVpyclZkQmRRa2dnOTBJZC1lME5PWFFIdWl3MkFLTnlrSFJJb1VVMHQzalJYRVFTZHp1MDVjMFNqM2tyeTJIWTMtaDRET3ZEMlhTeTNJSFNMYzN3RHp2VTVqTEpMTWlRYkg1NmwtckxsX19BeER2b19WSGNqaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQeko3RTYySVl3TGhzcDUxaEwyazBSQ0FlU1ZtVEprLXRKV2ZSU1dNVjJxT0draG1IM0Y3cG5DWjhUbkNtLVBvNjZFVXRlWmpRTFdUMTZWZHVzTG5DaU5RZ1VHQTlWYmFaaERJV3JjSUZicFo2TURxb3FEQlFPOWd4OE5ZcjZ1TTdlbFRmMEhJbHY4Wko4N2pDaWYtMlZUTkc2aW84Nw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gJBVV95cUxQUjlGUTc2Rnp5WHRrZ3pwemg1ME0xcklhMzRjSHdKbVdDZDV2eFk5bGNIUTFySjJZQWpwREh0NEZ0TjVPZ2UxWjZkaXQzLWF5UUNoWW5BRk9pVEEwcHlheXpqaWFXWXhJTkxrQUpyUHhXaXZtbDZVbTg1bDRMV2l2bklzRmNWbXJBQlJXcG9DbmRiQzc0Q3FJUVBYZElnYjYyaU9vVWNYTk1CRk5iQUtSZEVDY2lDOWdVMkhqbFg4aVBPNXR3dGFOazEtWGhzb1RJLWduNTRDTmNxZURPQzRZSVNSUG1pbjlIaC1uMUo5azBkODczQ3RBTWtEeElzRUJybm5lQWZvcU9lcTd4Wk5qbDhXU24zUkhDNFZEbzUzb29vU1lBeFhWMTFqOVAwUkJhTDdTYVdFSXE5ZWJuV2tKYzZVXzFJdTZyUTMxZjVFenlHSVQ1ZjJQSzhlWE9UeG5aV0E?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywJBVV95cUxNTHE5blRGNVNmTDE2OTVuMXdxc2pWbG5zdFFnQzhHckVJRTZzd0E3bjZ4SzFBcWNTVzQxRzNEcm41RHY1bnJoWV9vOGFrNGduQmE3bWE0OHlvbEU5NDByeUgySWY4b0Fod3J6Znp0S2Zxa19NYkY1M0w0dUVFWnVyT01wbGotSTBWZXU4c2wxbF9CLWNQZjNmRTVSVWI4YjVBUTBJaVFFcnhmUl9iRnBzVk5CengwNV8wTHhZUmFveHBCUWN4ekZyc2pfRVlqemN4dVFnVm1BR0lRQVVTNkdtcDlIOTQteVA5OHNCLXZHQWhzdy0wN01rX3dwcjdTaldkWWItOS1CWWpMVlk4a1g4UTVVTVI1cE5rNjV5bEt6cnVZMUF1WUNJcXRJN2hfWVFBUTFEc19Oc3Bqa3ExeVlkcWh0dWM3S3d0c05N?oc=5", "source_name": "Business Wire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian's at-home TED shot nears FDA filing after Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPSTNpMzdtQU5Tb3J3ZGd1VTV1b1B1Y0pVZTE2VXRMelVNcHpnbmRZMG1QUkxMTVpYbGFRTnVEMk5qNmZ2LWVKc2NrQ2I3ZWh1M0dHbjhOWVhsTmxzcGcteXZpblhHWm1pMXRDdzJLaV9hTXQtM3l0cERZRmpqRTZDVkdnelZockw4MDlVSjhkTzMzZWFDMFdwQ3VaNC1rSzlLZ0dBNE5BVDk2TmZzeWZyc0J2R2NtM0k?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcUtaZFZzZXlaTjJjME0wZXA3MklPU3lCTzkwWXJILUJoZmVreW5kbklQbGxwZFlEMjVHSERBajhDUXZhTXR5TXZkX2k1ZUM4enFyaTc1QWFsVlhwT0g4R3BlNDZ6a0syWXZhczQ3VWNWeXliWEZpallNQWdJN3dnM05TZGxZRVJRcXN0NE5VeklYV3lJbGx2aGlnU1FNR3pfeUJrZF9HbjcwblE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTzdLNHVGcXVjVTB4YV9DX3NEOGN6VU1wUjRTb0Q0Y1FtbmlaTDVieWJoTmpMYldHdHp1Y2FiQzhONWZ1eUxjc0RFU2ZkVnFNVjNfdmZteXRfZ09uQ1Zwa1Q4X1l1SC1vZmd1RGNtMnNYbWJXbS1sQTNzekpJSHM5WG80TDdsT21NMVFMX1FvUjNSeEtQMW1RT3Q5alFhQ2l5OEEtUy1kSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNYWRUSHplT0x5dmwtbV9lYU1XXzZZWkxDVHBBRGlXTDZGN0s5NmNyZmVtY1NmSTNMRExmdmxNUUx4UVZVX2VMcTVZMzdUX1djbEhQeFp2NU9xanZmYTlzRVM1M0lnVVNzcTdaNUhxZEM5ZlhQNXRESGw4bUNGVmV5d3ZpN3huai1IcXBZU2dTVTEybnNkbUJhem15SWozZWc?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi\u2011Month Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNHpWNTRFSURCVTRGNEgwWlRPUEFOWjhkLWQ3NGxybzFXeV8tUHlMNzI3WmdpODZvSVNPRU5sa2tURG9mY0ZFWjRqX3N1SFpzd2NIZlVXSTlPWnVpVnZIV29GTXVBLWtjN0N6ZFVSYy1pam9pYWJHV0RZM2REUWNzWDdSRTVhRlRaYU4zMmd5MlQtVi1UQ3VXYUNSMUM0Rkg5emJpLS0xTWtpdw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUlZUMG43TGxidmdqay0wNTFaY2NhZTlaenNwY1FyZjNrUUpVMDExQkJvMFRDQlpabE5acTlJUVpMamxCc20yazdta0ZqVDVfWkpMdFlTbWFoY3ctd081anU4enpfYmxMNGt6Y3EtdUplekZsMU93d2JFYV9lNi1aUkI4TExrSXhxVjB1TzdXUzRRTVZNVG1hOVFjQ0hBaGk3?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics\u2019 stock sinks despite positive Phase III TED data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQclNBOGZ5OU54Qk9QdmU2SElyS2hBbXgwOHFGblNCN2l1RXZoaGNFVENldGdCSW52TlhwV0dZeVlVN3VXdVlBcDJpTTN2aDV4LTk2UEN4YWpfbi14S0VjX1o0bGpMRnppRUJ3Q1ExbEM3U3BDV0pmS0xXajdYQXJEcWZFOUNSTFNGbVhkYnY0YjFIV2VnOHRlYk50cmhfelZJeXdiYXZiMGd6TTJhT2hGTw?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Lumvoa\u2019s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNR29uSk1XdV9XREhNejhocjNzUWtfUVpaZmszcXB3NkVLZl9HaFpYVk1oeVYzTTI1TkZFdm1PYkRtREJYdXdmbXRRUGZjZ0tGS1ViQVVyVk1ORnVrN2pEOWd4WS0wODgzUGdld0lrR3h1N0s2OGp6akdjSEtjUk5pZnJ5MlFNaUVfR3B6eDJlMFhxTHN0TE1FVU8ycFdrZw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T14:01:48+00:00", "published_display": "15 Jul 2026 14:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMVJZaGRacTlPN0lhMUVONVVxRXZadFhJOTc5NUdKNy1vb0JpLThmWVBBOTNvNWdGOXA1Vmo4SVRIQkgzc1dWMGg5LWkwa2RxSGRGTU1SMnFzdTI5LVI3NE9xNnhwdF8tcE4yYnZ5ZkF5cGRrWVd6QlBidW03SUNSd1JEcGRCeUxpa3pFU3BlNkRlV2NkWVFyZGUxZWtLRVlILUMtQWM5MA?oc=5", "source_name": "Market source", "published_at": "2026-07-15T12:24:01+00:00", "published_display": "15 Jul 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today", "summary": "Viridian Therapeutics (VRDN) stock has dropped 37.8% year-to-date, but despite this decline, valuation checks suggest it remains expensive, trading at a high P/S ratio of 29.7x compared to industry averages. The tailored Fair Ratio further indicates overvaluation, although this c", "url": "https://finance.yahoo.com/markets/stocks/articles/viridian-therapeutics-vrdn-stock-still-051014266.html", "source_name": "Market source", "published_at": "2026-07-15T12:11:55", "published_display": "15 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN6389238 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides key details about the Viridian Therapeutics, Inc. VRDN6389238 bond. It highlights the current coupon rate of 1.75% and indicates that the next interest payment is scheduled for November 16, 2026. The piece also notes that further in-depth coupon data and an ", "url": "https://www.tradingview.com/symbols/FINRA-VRDN6389238/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-15T04:11:55", "published_display": "15 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN6389238 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Viridian Therapeutics, Inc. bond, VRDN6389238, which has a 1.75% coupon and matures on May 15, 2032. It details the issuer's profile as a biopharmaceutical company focused on autoimmune and rare diseases. The bond has an outstanding amoun", "url": "https://www.tradingview.com/symbols/FINRA-VRDN6389238/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T16:11:55", "published_display": "14 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43", "summary": "Wedbush analyst Laura Chico has reiterated a Buy rating for Viridian Therapeutics (VRDN.US) and maintained a target price of $43. According to TipRanks data, Chico demonstrates a 53.7% success rate and a 14.6% average return over the past year, indicating a positive track record ", "url": "https://www.moomoo.com/news/post/72868295/wedbush-maintains-viridian-therapeutics-vrdnus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-14T14:11:41", "published_display": "14 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval", "summary": "Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its first commercial product, which has positively impacted its stock performance with significant short-term gains. Despite a high Price-to-Sales ratio of 31.5x, suggesting overvaluation compared to industry", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-could-be-87-below-fair-value-afte", "source_name": "Simply Wall Street", "published_at": "2026-07-10T23:41:13", "published_display": "10 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total debt per share of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "This article provides financial data for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its total debt per share. It presents the period, value, and change percentages related to this metric, indicating what appears to be part of a financial report or overview.", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-statistics-and-ratios/total-debt-per-share/", "source_name": "TradingView", "published_at": "2026-07-10T12:10:22", "published_display": "10 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total assets of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "The article focuses on the total assets of Viridian Therapeutics, Inc., identifiable by its Hamburg Stock Exchange ticker 1S1. It appears to be a stub or financial data page rather than a detailed news article, providing context within TradingView's platform. The content primaril", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-balance-sheet/total-assets/", "source_name": "TradingView", "published_at": "2026-07-10T11:40:22", "published_display": "10 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tangible book value per share of Viridian Therapeutics, Inc. \u2013 HAM:1S1", "summary": "The article provides financial information for Viridian Therapeutics, Inc. (HAM:1S1), specifically focusing on its tangible book value per share. It appears to be a financial data snippet from TradingView, indicating the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/HAM-1S1/financials-statistics-and-ratios/book-tangible-per-share/", "source_name": "TradingView", "published_at": "2026-07-09T19:05:03", "published_display": "09 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline", "summary": "Viridian Therapeutics, a Nasdaq-listed biotech, is focused on developing antibody-based treatments for thyroid eye disease and similar autoimmune conditions affecting the eye. The company aims to expand its pipeline and collaborate with manufacturing partners to achieve long-term", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/viridian-therapeutics-outlines-eye-disease-strategy-as-nasdaq-listed/69725079", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T15:39:13", "published_display": "08 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances", "summary": "Viridian Therapeutics (VRDN) is a clinical-stage biotechnology company focusing on autoimmune and rare diseases, particularly advancing its pipeline strategy for thyroid eye disease. The company's lead monoclonal antibody program targets specific immune pathways for this conditio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/viridian-therapeutics-updates-pipeline-plans-as-thyroid-eye-disease/69717392", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:57:00", "published_display": "07 Jul 2026 21:57", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wedbush-sees-commercial-edge-viridian-172141387.html", "source_name": "Insider Monkey", "published_at": "2026-07-06T17:21:41+00:00", "published_display": "06 Jul 2026 17:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease", "summary": "Viridian Therapeutics recently received FDA approval for Lumvoa (veligrotug-vvze) for both active and chronic thyroid eye disease, marking its first commercial product and a significant shift in its investment narrative. The company now faces the challenge of converting this appr", "url": "https://www.sahmcapital.com/news/content/the-bull-case-for-viridian-therapeutics-vrdn-could-change-following-fda-approval-of-lumvoa-for-thyroid-eye-disease-2026-07-06", "source_name": "Sahm", "published_at": "2026-07-06T10:10:42", "published_display": "06 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN - Viridian Therapeutics Inc Earnings", "summary": "This article provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also presents earnings per share (EPS) forecasts, insider and institutional ownership ", "url": "https://finviz.com/stock?t=VRDN&b=2&p=d&ty=ea", "source_name": "Finviz", "published_at": "2026-07-05T00:09:40", "published_display": "05 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Viridian Therapeutics Inc (VRDN)", "summary": "This article analyzes hypothetical investments in Viridian Therapeutics Inc (VRDN), detailing the returns of $1,000 invested over 1, 5, and 10 years, and comparing its performance to the S&P 500. It also provides an in-depth company profile, outlining Viridian's focus on developi", "url": "https://www.stocktitan.net/tools/stock-return-calculator/VRDN", "source_name": "Stock Titan", "published_at": "2026-07-04T08:40:34", "published_display": "04 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ajer granted 32,341 Viridian Therapeutics (VRDN) stock options at $18.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPQjRrM0xKXzFVWlNleUlEN1dseF9WdzJkYjN2THhNdTdpOG5LcHE4dGYzYXVRejFOcXoyT1l3MGVKTjNfTXhXVndNZEhYaC1rUi0wcUJDaFFUSWJzT0JrcjlPX0tWNU8zd0FaRFJOUjF2ZmJZLU0ySkUxbEpCaHFpWHBHTzdRY2FnM3g0bHVVU3FybUdHanNZbTduSnY4dFFwWkFOZzhfUGdEcjQ2Z09RNDU1ZnA5R28xZklPdnFoYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:17:15+00:00", "published_display": "02 Jul 2026 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQWWNCY2toUTl2WlJ2X0I3OXo1YVozd2w0YkMxM1FpcWduLXFFTDhOMUQ4bUJDeHlOQm1RelFNZVM1dEN4TllESHUtNEV6ZTI0S2RQUG5GRXBENjk1NG42aWZ2cnJUcGdnQjdidk9uZWJvODFtRkdVMlFnZ3lZRFhrVnRGQXQ2WjFlYUNNSmx0MlhLdEVXLVZweHN4SDdOd2JRV1U3Yi1HQkJua0VIcWxEWUlnUEdSUnk0RkMyb1Jrbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know", "summary": "Shares of Viridian Therapeutics (VRDN) rose 6.3% last week following FDA approval for veligrotug (brand name Lumvoa) for thyroid eye disease (TED), marking the company's entry into the commercial biotechnology sector. Lumvoa is the first FDA-approved TED therapy with labeling for", "url": "https://finance.yahoo.com/healthcare/articles/vrdn-stock-rises-6-3-144100711.html", "source_name": "Market source", "published_at": "2026-07-01T14:41:00", "published_display": "01 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more", "summary": "This edition of Rx Rundown covers significant news in the medical marketing and pharmaceutical industry. Key highlights include Zymeworks acquiring Theravance Biopharma, several FDA approvals and rejections for new and existing drugs, and substantial funding rounds for various bi", "url": "https://www.mmm-online.com/news/rx-rundown-zymeworks-viridian-therapeutics-biocryst-and-more/", "source_name": "Medical Marketing and Media", "published_at": "2026-07-01T11:39:33", "published_display": "01 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN - Viridian Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short", "url": "https://finviz.com/stock?t=VRDN&ty=oc&ov=chain_strike&s=20", "source_name": "Finviz", "published_at": "2026-07-01T08:10:07", "published_display": "01 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Wins FDA Approval For Lumvoa, Is The Upside Already Priced In?", "summary": "Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its treatment for thyroid eye disease, leading to a 6% after-hours stock increase. Despite a 40.11% year-to-date drop, the stock shows a 26.99% one-year return, prompting questions about its current valuation", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/viridian-therapeutics-vrdn-wins-fda-approval-for-lumvoa-is-t", "source_name": "Simply Wall Street", "published_at": "2026-07-01T07:10:42", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Viridian's veligrotug for TED as Lumvoa", "summary": "Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking it as the second FDA-approved treatment for the condition. Lumvoa is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in", "url": "https://glance.eyesoneyecare.com/stories/2026-06-30/fda-clears-viridian-s-veligrotug-for-ted-as-lumvoa/", "source_name": "Eyes On Eyecare", "published_at": "2026-06-30T18:53:13", "published_display": "30 Jun 2026 18:53", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/viridian-therapeutics-apos-lumvoa-could-155322062.html", "source_name": "MT Newswires", "published_at": "2026-06-30T15:53:22+00:00", "published_display": "30 Jun 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian may have edge over Amgen in eye drug showdown, analysts argue", "summary": "", "url": "https://finance.yahoo.com/m/c09c12d4-6ec1-3a49-b338-7aa08274d43d/viridian-may-have-edge-over.html", "source_name": "BioPharma Dive", "published_at": "2026-06-30T11:33:00+00:00", "published_display": "30 Jun 2026 11:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-lifts-price-target-viridian-113014022.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:30:14+00:00", "published_display": "30 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED)", "summary": "Viridian Therapeutics announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), following priority review and support from the THRIVE and THRIVE-2 clinical trials. The company plans an immediate launch and has established Viridia", "url": "https://www.visionmonday.com/eyecare/article/viridian-therapeutics-receives-fda-approval-for-lumvoa-for-the-treatment-of-thyroid-eye-disease-ted/", "source_name": "VisionMonday.com", "published_at": "2026-06-30T04:10:13", "published_display": "30 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Viridian Therapeutics Price Target to $43 From $32, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-lifts-viridian-therapeutics-price-185123743.html", "source_name": "MT Newswires", "published_at": "2026-06-29T18:51:23+00:00", "published_display": "29 Jun 2026 18:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Metals Inc (VRDN) Stock Forum and Discussion", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxQN0xkUGVUWFVQeThLRm1peUgwaVhKcjdEb0xJbmE3bXVyMmZaOWlkQTc4cTZYcjAweEx5Y3RKWTJZNDBxWHI2UjNzX3JVLUowcjM3eGpfbWdLMnFiOTgyX0VpMHJPM0FYQUFhNnNJUUVLZVpTaVhicW9WNkdQbVlSVHMzeEdxMmtCRWpiWDVMOGVrS3dTR0xaNDJGRXVuMThfdnBDTkEtQ2plelVKVXN5MnVBN1hvUkpnTlZqUldlZVljakFjeXMyUUpSczRhY0IwcU1WVGlBSzNKLWpJSk9jVFhNNUVrUjhmbHY4RjRDbldXT2pxUjluODY0YzM2X25YNlR0UW1oWmlGelc3QjZtQS1fM2tzOUtwNHFtUmRJVzgwY2xO?oc=5", "source_name": "Moomoo", "published_at": "2026-06-29T17:57:00+00:00", "published_display": "29 Jun 2026 17:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutic stock rating reiterated at Outperform by William Blair", "summary": "William Blair has reiterated its Outperform rating on Viridian Therapeutic (NASDAQ:VRDN) following the company's recent discussion of its newly FDA-approved treatment for thyroid eye disease, Lumvoa. The firm expressed increased confidence in Viridian's commercial readiness and t", "url": "https://www.investing.com/news/analyst-ratings/viridian-therapeutic-stock-rating-reiterated-at-outperform-by-william-blair-93CH-4765927", "source_name": "Investing.com", "published_at": "2026-06-29T17:41:26", "published_display": "29 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)", "summary": "Analysts are showing bullish sentiment towards several healthcare stocks, including Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595), and Sino Biopharmaceutical (SBMFF). Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeu", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3028401/analysts-are-bullish-on-these-healthcare-stocks-viridian-therapeutics-vrdn-genfleet-therapeutics-shanghai-inc-class-h-hk2595/", "source_name": "The Globe and Mail", "published_at": "2026-06-29T08:41:26", "published_display": "29 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Viridian Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQR09YVWJxZ0E3b0hMTEh5OGxqSkdWbkVkY3NDa1NlbWJDbGdhMTVjc3hFb2drZVlvU3lfSm9ld256V1M2Wk02VG5DTkMxanF4enI5YWhuMGx1UmpDSHVfX2dWeVNESGRQOEkycXQ3YXBjMUd6OEJqV0JheHlJYWVvYVRBX1ZmXzlSdWU4Y1JKampHQkhCejdvLWdfUnNvUWVycHlMU3RyYm1PaFpoWGdB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa\u2122 (veligrotug-vvze) for the Treatment of Thyroid Eye Disease", "summary": "Viridian Therapeutics has received U.S. FDA approval for Lumvoa\u2122 (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking the company's first commercial product. Lumvoa is the first approved treatment for TED with data for both active and chronic forms of the dis", "url": "https://www.biospace.com/press-releases/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-lumvoa-veligrotug-vvze-for-the-treatment-of-thyroid-eye-disease", "source_name": "BioSpace", "published_at": "2026-06-29T07:10:42", "published_display": "29 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All\u2011Stage Thyroid Eye Drug", "summary": "Viridian Therapeutics' stock rose by 7.6% after its drug Lumvoa received FDA approval to treat thyroid eye disease across all stages, making it the first such therapy. This approval shifts Viridian from a development-stage company to a commercial one, with potential for further m", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/why-viridian-therapeutics-vrdn-is-up-76-after-fda-clears-fir", "source_name": "Simply Wall Street", "published_at": "2026-06-29T03:39:43", "published_display": "29 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Viridian Therapeutics, Inc. \u2013 NASDAQ:VRDN", "summary": "This article provides financial information for Viridian Therapeutics, Inc. (NASDAQ:VRDN), specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed at the time of publication and offers an overview of the company's financial data on T", "url": "https://www.tradingview.com/symbols/NASDAQ-VRDN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:39:43", "published_display": "28 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Viridian Therapeutics, Inc. \u2013 GETTEX:1S1", "summary": "The article displays the \"Price to earnings forward\" for Viridian Therapeutics, Inc. (1S1) traded on Gettex, indicating that the market was closed with no trades recorded for this metric. It also mentions that the data is provided by ICE Data Services and FactSet, and refers to S", "url": "https://www.tradingview.com/symbols/GETTEX-1S1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:37", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian\u2019s Lumvoa becomes the first FDA-approved TED treatment", "summary": "Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) to treat Thyroid Eye Disease (TED), making it the first approved TED treatment with data for both active and chronic forms of the condition. The approval is supported by positive results from the THRIVE ", "url": "https://www.stocktitan.net/news/VRDN/viridian-therapeutics-announces-u-s-fda-approval-and-launch-of-w6eswct1do92.html", "source_name": "Stock Titan", "published_at": "2026-06-27T06:39:43", "published_display": "27 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval", "summary": "Viridian Therapeutics Inc (VRDN) saw its stock jump 6% after-hours following FDA approval of its drug, Lumvoa, for thyroid eye disease (TED). Lumvoa is the first treatment for TED approved for both active and chronic stages of the condition. The approval is based on strong result", "url": "https://stocktwits.com/news-articles/markets/equity/vrdn-stock-jumps-after-hours-as-viridian-wins-first-fda-approval/cZ1225pR7WO", "source_name": "Stocktwits", "published_at": "2026-06-26T23:11:17", "published_display": "26 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Paradigm entities report combined stake in Viridian Therapeutics (NASDAQ: VRDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPZmVnMmhxazZaTjBneEtiLWZqbWdqdlNOM1ZtM2ZNREJZM00taUJIOUVJdDBad1V5NENZMi11Z1JLVVd6NzRIa19jeVJYOV9rQmJMbERrNEdiTHNkWkxQaDZYdGgwRW5NTkp1aVdqbkQxWUxVX3JlS0N2b29Uc29xdzNWdGt4YmhLZUhaMGxPZUxWaExWbzlMeng1WUNCV0k5V0Vvay1vVEZydzNYUHljajhtbDRJZnRJUFh0QXducVY3b1BjNjhJd1NfNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves Lumvoa for thyroid eye disease as Viridian (VRDN) readies launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb2t0cmhPd0dKMjFfSTFNWGNzTFJaLTZDWHdITzRYcUpRSmtlTldSa2pzaGIxYmFfZ0tEMDQwem9LeWd4YndMOFVYdzhuNTlxbjlPNlE3WURiTXBkMGlIVTZBXzg3ZklVQm9EMVU1QWJ1SXlsUDliU2h5ZFpkRVpHWFQxem5ScHRRRFJNV0lzZnFva0pvdzgwRFZpSXFmd0lPLU1UbjB6NGJIamRQdnRmT09TY3FSNkhv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOd2pzX0Zyd3FnY0FQR2EwbldnX09FLVhaRG80bk5wN2lQX1VZRG5aSnF6MzMxR3Vkd3JEV3JyOGZ1eS1maG0zdUNHLXVJNGczUzd2eXkxaXJyaEJnNERYLVZkdGxvS2JHYkdzMldqX1VVdkdVdzFjOGxydW81SmtTVmZTU19UZUtfZDZxekRHQzVfeHFfbks2aF9FRlBWUW5pVzZOTWFZOWV0dw?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOVHBoYmJaWFVkX1VCWFZiWEN5R2QtM2liZEVsM3Q4cVRHenRRSG9WRkNZbFFLNU5EMnBOQmVZbEV6Rkh5RkFEdnhuQVpyclZkQmRRa2dnOTBJZC1lME5PWFFIdWl3MkFLTnlrSFJJb1VVMHQzalJYRVFTZHp1MDVjMFNqM2tyeTJIWTMtaDRET3ZEMlhTeTNJSFNMYzN3RHp2VTVqTEpMTWlRYkg1NmwtckxsX19BeER2b19WSGNqaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQeko3RTYySVl3TGhzcDUxaEwyazBSQ0FlU1ZtVEprLXRKV2ZSU1dNVjJxT0draG1IM0Y3cG5DWjhUbkNtLVBvNjZFVXRlWmpRTFdUMTZWZHVzTG5DaU5RZ1VHQTlWYmFaaERJV3JjSUZicFo2TURxb3FEQlFPOWd4OE5ZcjZ1TTdlbFRmMEhJbHY4Wko4N2pDaWYtMlZUTkc2aW84Nw?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gJBVV95cUxQUjlGUTc2Rnp5WHRrZ3pwemg1ME0xcklhMzRjSHdKbVdDZDV2eFk5bGNIUTFySjJZQWpwREh0NEZ0TjVPZ2UxWjZkaXQzLWF5UUNoWW5BRk9pVEEwcHlheXpqaWFXWXhJTkxrQUpyUHhXaXZtbDZVbTg1bDRMV2l2bklzRmNWbXJBQlJXcG9DbmRiQzc0Q3FJUVBYZElnYjYyaU9vVWNYTk1CRk5iQUtSZEVDY2lDOWdVMkhqbFg4aVBPNXR3dGFOazEtWGhzb1RJLWduNTRDTmNxZURPQzRZSVNSUG1pbjlIaC1uMUo5azBkODczQ3RBTWtEeElzRUJybm5lQWZvcU9lcTd4Wk5qbDhXU24zUkhDNFZEbzUzb29vU1lBeFhWMTFqOVAwUkJhTDdTYVdFSXE5ZWJuV2tKYzZVXzFJdTZyUTMxZjVFenlHSVQ1ZjJQSzhlWE9UeG5aV0E?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywJBVV95cUxNTHE5blRGNVNmTDE2OTVuMXdxc2pWbG5zdFFnQzhHckVJRTZzd0E3bjZ4SzFBcWNTVzQxRzNEcm41RHY1bnJoWV9vOGFrNGduQmE3bWE0OHlvbEU5NDByeUgySWY4b0Fod3J6Znp0S2Zxa19NYkY1M0w0dUVFWnVyT01wbGotSTBWZXU4c2wxbF9CLWNQZjNmRTVSVWI4YjVBUTBJaVFFcnhmUl9iRnBzVk5CengwNV8wTHhZUmFveHBCUWN4ekZyc2pfRVlqemN4dVFnVm1BR0lRQVVTNkdtcDlIOTQteVA5OHNCLXZHQWhzdy0wN01rX3dwcjdTaldkWWItOS1CWWpMVlk4a1g4UTVVTVI1cE5rNjV5bEt6cnVZMUF1WUNJcXRJN2hfWVFBUTFEc19Oc3Bqa3ExeVlkcWh0dWM3S3d0c05N?oc=5", "source_name": "Business Wire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian's at-home TED shot nears FDA filing after Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPSTNpMzdtQU5Tb3J3ZGd1VTV1b1B1Y0pVZTE2VXRMelVNcHpnbmRZMG1QUkxMTVpYbGFRTnVEMk5qNmZ2LWVKc2NrQ2I3ZWh1M0dHbjhOWVhsTmxzcGcteXZpblhHWm1pMXRDdzJLaV9hTXQtM3l0cERZRmpqRTZDVkdnelZockw4MDlVSjhkTzMzZWFDMFdwQ3VaNC1rSzlLZ0dBNE5BVDk2TmZzeWZyc0J2R2NtM0k?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNcUtaZFZzZXlaTjJjME0wZXA3MklPU3lCTzkwWXJILUJoZmVreW5kbklQbGxwZFlEMjVHSERBajhDUXZhTXR5TXZkX2k1ZUM4enFyaTc1QWFsVlhwT0g4R3BlNDZ6a0syWXZhczQ3VWNWeXliWEZpallNQWdJN3dnM05TZGxZRVJRcXN0NE5VeklYV3lJbGx2aGlnU1FNR3pfeUJrZF9HbjcwblE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTzdLNHVGcXVjVTB4YV9DX3NEOGN6VU1wUjRTb0Q0Y1FtbmlaTDVieWJoTmpMYldHdHp1Y2FiQzhONWZ1eUxjc0RFU2ZkVnFNVjNfdmZteXRfZ09uQ1Zwa1Q4X1l1SC1vZmd1RGNtMnNYbWJXbS1sQTNzekpJSHM5WG80TDdsT21NMVFMX1FvUjNSeEtQMW1RT3Q5alFhQ2l5OEEtUy1kSQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNYWRUSHplT0x5dmwtbV9lYU1XXzZZWkxDVHBBRGlXTDZGN0s5NmNyZmVtY1NmSTNMRExmdmxNUUx4UVZVX2VMcTVZMzdUX1djbEhQeFp2NU9xanZmYTlzRVM1M0lnVVNzcTdaNUhxZEM5ZlhQNXRESGw4bUNGVmV5d3ZpN3huai1IcXBZU2dTVTEybnNkbUJhem15SWozZWc?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi\u2011Month Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNHpWNTRFSURCVTRGNEgwWlRPUEFOWjhkLWQ3NGxybzFXeV8tUHlMNzI3WmdpODZvSVNPRU5sa2tURG9mY0ZFWjRqX3N1SFpzd2NIZlVXSTlPWnVpVnZIV29GTXVBLWtjN0N6ZFVSYy1pam9pYWJHV0RZM2REUWNzWDdSRTVhRlRaYU4zMmd5MlQtVi1UQ3VXYUNSMUM0Rkg5emJpLS0xTWtpdw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQUlZUMG43TGxidmdqay0wNTFaY2NhZTlaenNwY1FyZjNrUUpVMDExQkJvMFRDQlpabE5acTlJUVpMamxCc20yazdta0ZqVDVfWkpMdFlTbWFoY3ctd081anU4enpfYmxMNGt6Y3EtdUplekZsMU93d2JFYV9lNi1aUkI4TExrSXhxVjB1TzdXUzRRTVZNVG1hOVFjQ0hBaGk3?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viridian Therapeutics\u2019 stock sinks despite positive Phase III TED data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQclNBOGZ5OU54Qk9QdmU2SElyS2hBbXgwOHFGblNCN2l1RXZoaGNFVENldGdCSW52TlhwV0dZeVlVN3VXdVlBcDJpTTN2aDV4LTk2UEN4YWpfbi14S0VjX1o0bGpMRnppRUJ3Q1ExbEM3U3BDV0pmS0xXajdYQXJEcWZFOUNSTFNGbVhkYnY0YjFIV2VnOHRlYk50cmhfelZJeXdiYXZiMGd6TTJhT2hGTw?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 62, "sentiment_summary": {"positive": 21, "negative": 3, "neutral": 38, "score": 59, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 6.32, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 19.74, "latest_week": "2026-07-10", "one_week_move": 1.8, "four_week_move": 20.7, "twelve_week_move": 33.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.122606, "market_dynamics_buy_signal": true, "relative_strength": -27.083883, "fair_value_gap": 4.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.183, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.8% over one week, +20.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": ["Market Dynamics buy signal"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "Simply Wall Street", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 6}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 9}, {"label": "Analyst action", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.8% over one week, +20.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lumvoa\u2019s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)"}], "updated_at": "2026-07-16T06:46:01.644863+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}